| Shiqiang Tian, MD | |
|
1 Kettle Point Ave, East Providence, RI 02914-5375 | |
| (401) 330-1450 | |
| Not Available |
| Full Name | Shiqiang Tian |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 27 Years |
| Location | 1 Kettle Point Ave, East Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275821738 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rhode Island Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Orthopedics Inc | 9931000395 | 156 |
| University Orthopedics Inc | 9931000395 | 156 |
News Archive
Screening for Mental Health, Inc. (SMH) today announced that they have received funding from the Department of Defense (DoD) to continue their work with Military Pathways™, a mental health awareness and education program that offers free, anonymous mental health self-assessments to veterans and personnel from all branches of the military as well as their families.
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.
Alliant Pharmaceuticals has announced FDA approval of Methylin Chewable Tablets and Methylin Oral Solution for the treatment of ADHD. The two products are the first, and only, chewable tablet and oral solution for ADHD to gain FDA acceptance.
Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA.
For prostate cancer patients who had their prostates surgically removed, patient-physician communication was key for helping them cope with their disease and for improving their health-related quality of life.
› Verified 7 days ago
| Entity Name | University Orthopedics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235181041 PECOS PAC ID: 9931000395 Enrollment ID: O20040119000129 |
News Archive
Screening for Mental Health, Inc. (SMH) today announced that they have received funding from the Department of Defense (DoD) to continue their work with Military Pathways™, a mental health awareness and education program that offers free, anonymous mental health self-assessments to veterans and personnel from all branches of the military as well as their families.
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.
Alliant Pharmaceuticals has announced FDA approval of Methylin Chewable Tablets and Methylin Oral Solution for the treatment of ADHD. The two products are the first, and only, chewable tablet and oral solution for ADHD to gain FDA acceptance.
Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA.
For prostate cancer patients who had their prostates surgically removed, patient-physician communication was key for helping them cope with their disease and for improving their health-related quality of life.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shiqiang Tian, MD Po Box 1119, Providence, RI 02901-1119 Ph: () - | Shiqiang Tian, MD 1 Kettle Point Ave, East Providence, RI 02914-5375 Ph: (401) 330-1450 |
News Archive
Screening for Mental Health, Inc. (SMH) today announced that they have received funding from the Department of Defense (DoD) to continue their work with Military Pathways™, a mental health awareness and education program that offers free, anonymous mental health self-assessments to veterans and personnel from all branches of the military as well as their families.
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.
Alliant Pharmaceuticals has announced FDA approval of Methylin Chewable Tablets and Methylin Oral Solution for the treatment of ADHD. The two products are the first, and only, chewable tablet and oral solution for ADHD to gain FDA acceptance.
Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA.
For prostate cancer patients who had their prostates surgically removed, patient-physician communication was key for helping them cope with their disease and for improving their health-related quality of life.
› Verified 7 days ago